AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 294 min read$CLMB

Climb Global Solutions Reports Second Quarter 2026 Results

Climb Global Solutions, Inc. (CLMB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Global Solutions Reports Second Quarter 2026 Results Net Sales up 9% to $174.2 Million; Gross Billings up 17% to $587.3 Million; Gross Profit up 15% to $30.2 Million EATONTOWN, N.J., July 29, 2026 – Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Co

Original reporting
SEC EDGAR 8-K
Published Jul 29, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CLMB
Neutral
medium confidence
Mentioned
$CLMB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLMBNeutralMed
01

Why it matters

The key trade question is whether the market will reward the double-digit growth in gross billings and net sales despite weaker effective margin and slightly lower net income versus the prior year quarter.

02

Market read

Fresh quarterly financial datapoints (sales, billings, margins, cash, debt) can drive repricing and set expectations for the upcoming earnings call Q&A.

03

What to watch

Adjusted EBITDA was nearly flat and effective margin fell sharply; traders may need management commentary on normalization of costs and the path to the stated FY2025 adjusted EBITDA target by 2030.

Relevance 7/10Novelty 6/10Timing: after-hours Q2 2026 results filing, ahead of the 8:30 a.m. ET conference call July 30

Background

This is an SEC 8-K (Item 2.02) with Exhibit 99.1 reporting Climb Global Solutions’ Q2 2026 financial results and management commentary, plus a scheduled earnings call.

Company-level read

Ticker impact

$CLMBNeutralMedium confidence
Context

Climb reported Q2 2026 results with net sales up 9% to $174.2M and gross billings up 17% to $587.3M.

Expected impact

Near-term trading likely hinges on whether investors focus on growth (sales/billings) versus margin compression and higher SG&A.

Evidence & confidence

The filing provides concrete datapoints: growth in top-line and billings, cash increase, no debt, but margin deterioration and slightly lower net income versus the prior year quarter.

Market effects

Sector

Signals demand resilience in IT channel/distribution, but highlights cost pressure and margin sensitivity for value-added resellers.

Regional

Notes organic growth in both North America and Europe, with Europe flagged as a key focus area.

Global

Limited broader read-across; primarily company-specific performance and acquisition contribution (Interworks).

Counterpoint

What could challenge this read

Margin compression may be temporary due to acquisition-related SG&A and legal/professional costs, while billings growth suggests underlying demand remains intact.

Key entities

  • company
    Climb Global Solutions, Inc.

    NASDAQ-listed IT channel company reporting Q2 2026 results and providing forward-looking commentary.

  • acquisition
    Interworks

    Acquisition referenced as contributing to Q2 growth after closing on February 24, 2026.

  • executive
    Dale Foster

    CEO quoted on growth execution, line-card strategy, and long-term EBITDA expectations.

Read at source← All news

Related articles

OCT 24
$CLMBMedAI 8/10

Climb Bio reports 38% immunologic remission in kidney trial

Climb Bio (NASDAQ: CLYM) reported initial Phase 2 trial results for its kidney-disease treatment, PrisMN, showing 38% immunologic remission in the low-dose cohort and a 70% reduction in disease-linked antibodies. The company plans to release additional data in 2027. Climb shares closed at $10.19 before the announcement. The trial aims to identify a dose for pivotal development, with no serious adverse events reported.

mugglehead.com2 min
OCT 28
$JMSBMed

John Marshall Bancorp, Inc. (JMSB): 3rd Quarter Net Income Increases 39.5% Versus Year Ago Quarter Funding, Asset Quality, and Capital Position Company for Anticipated Growth

John Marshall Bancorp, Inc. (JMSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For Immediate Release October 28, 2026 ​ 3 rd Quarter Net Income Increases 39.5% Versus Year Ago Quarter Funding, Asset Quality, and Capital Position Company for Anticipated Growth ​ Reston, VA – John Marshall Bancorp, Inc. (Nasdaq: JMSB) (the “Company”), parent comp

SEC EDGAR 8-K2 min
OCT 28
$FMXMed

OXXO Mexico's customer traffic was strongest in more than two years

FEMSA reported Q3 2026 results, with total revenues up 9.8% and operating income up 9.9% YoY. OXXO Mexico saw 10.3% revenue growth and 5.8% income growth, with strong customer traffic. Coca-Cola FEMSA reported 10.9% revenue growth and 15.4% income growth. The company updated its reporting segments and highlighted growth in digital platforms Spin by OXXO and Spin Premia.

stocktitan.net2 min